Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:49:38.889Z.
Calculation as of: 2026-10-06T19:49:38.889Z.
Quote observation: 2026-10-06T19:45:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2b785bc55096390182f69d3a0e2d020d3bb9b84e75505e860cfcb21a76503d6
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$268.75M
PE Ratio
N/A
TTM Avg
39.79
3Y Avg
40.81
5Y Avg
32.75
Market Cap
$261.58M
PE Ratio
N/A
TTM Avg
15.73
3Y Avg
15.73
5Y Avg
15.86
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $266.62M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $267.50M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $268.41M | N/A | 7.56 | 7.56 | 7.56 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $268.75M | N/A | 39.79 | 40.81 | 32.75 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $263.71M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $262.47M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.58M | N/A | 15.73 | 15.73 | 15.86 |
| Palisade Bio, Inc. (PALI)vs › | $261.10M | N/A | 4.44 | 4.44 | 4.44 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.33
Forward EPS (Est.)
$-0.33
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2022-03-02 | 176.11 |
| 2022-03-01 | 176.46 |
| 2022-02-28 | 176.28 |
| 2022-02-25 | 176.28 |
| 2022-02-24 | 176.11 |
| 2022-02-23 | 176.11 |
| 2022-02-22 | 176.11 |
| 2022-02-18 | 176.11 |
| 2022-02-17 | 175.93 |
| 2022-02-16 | 176.28 |
| 2022-02-15 | 176.11 |
| 2022-02-14 | 176.11 |
| 2022-02-11 | 175.22 |
| 2022-02-10 | 175.22 |
| 2022-02-09 | 175.22 |
| 2022-02-08 | 174.87 |
| 2022-02-07 | 174.87 |
| 2022-02-04 | 175.22 |
| 2022-02-03 | 175.40 |
| 2022-02-02 | 175.40 |
| 2022-02-01 | 175.40 |
| 2022-01-31 | 174.51 |
| 2022-01-28 | 174.87 |
| 2022-01-27 | 174.51 |
| 2022-01-26 | 174.51 |
| 2022-01-25 | 175.58 |
| 2022-01-24 | 175.04 |
| 2022-01-21 | 174.87 |
| 2022-01-20 | 174.87 |
| 2022-01-19 | 175.04 |
| 2022-01-18 | 175.22 |
| 2022-01-14 | 175.04 |
| 2022-01-13 | 175.04 |
| 2022-01-12 | 175.22 |
| 2022-01-11 | 175.40 |
| 2022-01-10 | 175.75 |
| 2022-01-07 | 175.04 |
| 2022-01-06 | 175.58 |
| 2022-01-05 | 175.58 |
| 2022-01-04 | 176.46 |
| 2022-01-03 | 176.11 |
| 2021-12-31 | 174.87 |
| 2021-12-30 | 175.04 |
| 2021-12-29 | 174.87 |
| 2021-12-28 | 175.58 |
| 2021-12-27 | 175.40 |
| 2021-12-23 | 176.46 |
| 2021-12-22 | 174.87 |
| 2021-12-21 | 175.75 |
| 2021-12-20 | 175.75 |
| 2021-12-17 | 175.22 |
| 2021-12-16 | 175.22 |
| 2021-12-15 | 175.58 |
| 2021-12-14 | 175.40 |
